Opinion
As demand for biotech talent increases, the need to offer competitive pay to the average employee puts financial pressure on companies to increase CEO pay as well.
Q4 and full-year 2022 financial statements have revealed several companies slashing I-O pipelines. Here are just some of the factors at play.
After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves.
The SVB failure appears to have been caused by an underwritten public offering to raise $2.25 billion to cover security losses announced during SVB’s Q1 2023 mid-quarter update.
Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.
The FDA’s top five approvals in 2022 represent an eclectic mix of cancer, cardiovascular and rare disease drugs.
A look at whether the new tax reform will really spur a M&A spending spree for drugmakers.
A look at whether big money and big deals will be in store for 2018.
Here are some thoughts on breaking into the biomechanical engineering market.
A look at the latest batch of FDA approvals this year.